Diabetic kidney disease (DKD) is one of the fastest growing causes of chronic kidney
disease and associated morbidity and mortality. Preclinical research has demonstrated the …

With the rising tide of fatty liver disease related to metabolic dysfunction worldwide, the
association of this common liver disease with chronic kidney disease (CKD) has become …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Importance Individually, cardiac, renal, and metabolic (CRM) conditions are common and
leading causes of death, disability, and health care–associated costs. However, the …

The prevalence of obesity has increased dramatically during the past decades, which has
been a major health problem. Since 1975, the number of people with obesity worldwide has …

Chronic kidney disease (CKD) is a complex condition with a prevalence of 10–15%
worldwide. An inverse-graded relationship exists between cardiovascular events and …

Abstract Abstract The European Society of Cardiology 2021 guideline on cardiovascular
(CV) disease (CVD) prevention in clinical practice has major implications for both CV risk …

Background Chronic kidney disease (CKD) has a rising global prevalence and is expected
to become the fifth leading cause of death by 2030. Increased albuminuria defines the early …

Abstract Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo
Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers …

What is known and objective Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are
one of the preferred approved treatment options for people with type 2 diabetes (T2D) and …